Literature DB >> 15551213

Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis.

T Mark Doherty1, Anja W Olsen, Joachim Weischenfeldt, Kris Huygen, Sushila D'Souza, Tatiana K Kondratieva, Vladimir V Yeremeev, Alexander S Apt, Barbel Raupach, Leander Grode, Stefan Kaufmann, Peter Andersen.   

Abstract

BACKGROUND: Studies of different vaccine constructs have demonstrated variable efficacy against Mycobacterium tuberculosis in animal models. Despite the fact that these vaccines have used one or another of a very small number of immunodominant antigens, a direct comparison of the relative efficacy of the antigens and delivery systems has been difficult, because the studies have used different parameters for assessment.
METHODS: We compared the efficacies of the most commonly used vaccine constructs--adjuvanted protein, plasmid DNA, and live bacterial vectors--bearing the immunodominant secreted antigens early secreted antigen target-6 and antigen 85B, either alone or as a fusion protein. Mice were vaccinated with these constructs, and the effects of different delivery systems on protective efficacy (as assessed by survival studies and by monitoring bacterial load) and antigen-specific responses (including the contribution of CD4 and CD8 T cells to these responses) were assayed by various methods.
RESULTS: The relative efficacy of different vaccines is dependent on the delivery system, the antigen, and the animal model. Likewise, the relative immunodominance of individual antigens in the fusion molecule is altered by the choice of delivery system.
CONCLUSION: These results clearly demonstrate the importance of assessing vaccine function by use of multiple parameters and indicate which parameters are most reliable for assessing vaccine efficacy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15551213     DOI: 10.1086/425931

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection.

Authors:  Else Marie Agger; Joseph P Cassidy; Joseph Brady; Karen S Korsholm; Carina Vingsbo-Lundberg; Peter Andersen
Journal:  Immunology       Date:  2008-01-12       Impact factor: 7.397

Review 2.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

3.  Enhanced anti-tuberculosis immunity by a TAT-Ag85B protein vaccine in a murine tuberculosis model.

Authors:  Hu Dong; Wu Jing; Xing Yingru; Wang Wenyang; Cai Ru; Ni Shengfa; Xu Congjing; Dai Jingjing; Wang Wan; He Jiang; Zhang Rongbo
Journal:  Pathog Glob Health       Date:  2015       Impact factor: 2.894

Review 4.  Vaccines for tuberculosis: novel concepts and recent progress.

Authors:  T Mark Doherty; Peter Andersen
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

5.  Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T Cells.

Authors:  Carla Palma; Silvia Vendetti; Antonio Cassone
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

6.  T cell reactivity against mycolyl transferase antigen 85 of M. tuberculosis in HIV-TB coinfected subjects and in AIDS patients suffering from tuberculosis and nontuberculous mycobacterial infections.

Authors:  Pascal Launois; Annie Drowart; Eliane Bourreau; Pierre Couppie; Claire-Michèle Farber; Jean-Paul Van Vooren; Kris Huygen
Journal:  Clin Dev Immunol       Date:  2010-09-27

7.  rBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B.

Authors:  Thomas P Gillis; Michael V Tullius; Marcus A Horwitz
Journal:  Infect Immun       Date:  2014-07-07       Impact factor: 3.441

8.  Primary activation of antigen-specific naive CD4+ and CD8+ T cells following intranasal vaccination with recombinant bacteria.

Authors:  Annalisa Ciabattini; Elena Pettini; Peter Andersen; Gianni Pozzi; Donata Medaglini
Journal:  Infect Immun       Date:  2008-10-06       Impact factor: 3.441

9.  Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy.

Authors:  Javaid A Sheikh; Gopal K Khuller; Indu Verma
Journal:  J Immune Based Ther Vaccines       Date:  2011-06-26

Review 10.  Confronting the scientific obstacles to global control of tuberculosis.

Authors:  Douglas B Young; Mark D Perkins; Ken Duncan; Clifton E Barry
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.